However, there is strong evidence from the preclinical and mechanistic studies on PARPi, that support the use of PARPi, irrespective of the BRCA1/2 status or the HR-mediated repair in triple negative breast cancer, and seems highly promising for the HER2 + tumors, that become resistant to trastuzumab [14,15,16]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.